clinical trials
clinical trials
Dragonfly Research, The Elliot Lewis Center’s research arm, is currently conducting many clinical trials for relapsing and progressive forms of multiple sclerosis. Ongoing research includes phase II and phase III clinical trials, as well as phase IV observational trials, investigating the efficacy of new and existing multiple sclerosis therapies.
Opportunities to enroll for studies at Dragonfly Research change regularly, and enrollment is limited. If you are interested in participating, we encourage you to contact us as soon as possible and check this page frequently. Our Clinical Research Coordinators can be reached at 781-591-8313.
The Elliot Lewis Center and Dragonfly Research also conduct independent research projects to address important clinical issues. Learn more here.
MUSETTE
Clinical Trial Opportunity for Patients with Relapsing Remitting Multiple Sclerosis
MUSETTE is a clinical trial for patients with Relapsing MS aged 18-55. Patients will receive Ocrevus for 4.5 years through the study. To be eligible patients must have at least one documented relapse in the past year, and must ambulate without assistance. Patients must NOT have received previous treatment with Ocrevus or Rituxan in the past two years.
In addition to collecting safety data, the study is evaluating the efficacy and safety of higher dose Ocrevus in adults with RMS.
The study requires MRIs every 6 months for the first year and then yearly following. The Ocrevus, MRIs, assessments, and physician appointments are all covered by the study.
GAVOTTE
Clinical Trial Opportunity for Patients with Primary Progressive Multiple Sclerosis
GAVOTTE is a clinical trial for patients with Primary Progressive MS aged 18-55. Patients will receive Ocrevus for 4.5 years through the study. To be eligible patients can use a cane or a walker, but not a wheelchair. Patients must NOT have received previous treatment with Ocrevus or Rituxan in the past two years.
In addition to collecting safety data, the study is evaluating the efficacy and safety of higher dose Ocrevus in adults with PPMS.
The study requires MRIs every 6 months for the first year and then yearly following. The Ocrevus, MRIs, assessments, and physician appointments are all covered by the study.
EXCHANGE
Clinical Trial Opportunity for Patients with Relapsing & Secondary Progressive MS
Patients aged 18-65 with Relapsing or Secondary Progressive MS may be eligible for treatment with Siponimod, an investigational MS therapy.
This study is tracking the tolerability of Siponimod and any potential immune effects. Siponimod is a once-daily pill and patients will receive 6 months of treatment through the study. After completing the study, patients will have the option to receive Siponimod through a managed access program until it becomes commercially available.
Patients must currently be treated with any oral or injectable MS therapy. Certain previous MS therapies may be exclusionary. The study requires 4 visits over the course of 6 months and does not require any MRIs. The medication, assessments, and physician appointments are covered by the study.
CONSONANCE
Clinical Trial Opportunity for Patients with Primary Progressive & Secondary Progressive MS
(Note: We are currently not enrolling for this trial but will re-open for enrollment in Spring 2022)
CONSONANCE is a clinical trial for patients with Primary and Secondary Progressive MS aged 18-65. Patients will receive Ocrevus for four years through the study. To be eligible patients can use a cane or a walker, but not a wheelchair. Patients must NOT have received previous treatment with Ocrevus or Rituxan.
In addition to collecting safety data, the study is investigating the use of smartphones to track patient symptoms. 75% of patients who enter the trial will receive a smartphone with daily and weekly tasks, tracking day-to-day symptoms.
The study requires MRIs every 6 months for the first year and then yearly following. The Ocrevus, MRIs, assessments, and physician appointments are all covered by the study.
Contact our Clinical Research Coordinators at 781-591-8313 for more information.